ReviewJAMA2008
Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
Review in JAMA, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01239901 (Iron-mediated Vascular Disease in Sickle Cell Disease.), which is not on this map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Iron-mediated Vascular Disease in Sickle Cell Disease.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Interventions for treating intrahepatic cholestasis in people with sickle cell disease.The Cochrane database of systematic reviews · 2020Pooled it
- Magnesium for treating sickle cell disease.The Cochrane database of systematic reviews · 2019Pooled it
- Interventions for treating intrahepatic cholestasis in people with sickle cell disease.The Cochrane database of systematic reviews · 2017Pooled it
- Magnesium for treating sickle cell disease.The Cochrane database of systematic reviews · 2017Pooled it
- A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction.British journal of haematology · 2011Trial
- Relevant insights from personalized inhaled carbon monoxide dosing in a safety study in pneumonia and ARDS.Respiratory research · 2026Article
- Article
- TSH Receptor Reduces Hemoglobin S Polymerization and Increases Deformability and Adhesion of Sickle Erythrocytes.Anemia · 2024Article
- Plasma Lipids and Lipoproteins in Sickle Cell Disease Patients in the Northern West Bank, Palestine.BioMed research international · 2021Article
- Heme Degradation in Pathophysiology of and Countermeasures to Inflammation-Associated Disease.International journal of molecular sciences · 2020Review
- Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure.Heart (British Cardiac Society) · 2020Review
- New Therapeutic Options for the Treatment of Sickle Cell Disease.Mediterranean journal of hematology and infectious diseases · 2019Review
- Low nitric oxide level is implicated in sickle cell disease and its complications in Ghana.Vascular health and risk management · 2018Article
- Novel in vivo and in vitro techniques to image and model the cerebral vasculature in sickle cell disease.Blood cells, molecules & diseases · 2017Review
- A treatment algorithm to identify therapeutic approaches for leg ulcers in patients with sickle cell disease.International wound journal · 2016Review
- Arginase Inhibition Reverses Endothelial Dysfunction, Pulmonary Hypertension, and Vascular Stiffness in Transgenic Sickle Cell Mice.Anesthesia and analgesia · 2016Article
- Gas what: NO is not the only answer to sexual function.British journal of pharmacology · 2015Review
- Vasculopathy and pulmonary hypertension in sickle cell disease.American journal of physiology. Lung cellular and molecular physiology · 2015Review
- Infection-related hemolysis and susceptibility to Gram-negative bacterial co-infection.Frontiers in microbiology · 2015Review
- Molecular pathophysiology of priapism: emerging targets.Current drug targets · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A 34-year-old African American woman with sickle cell disease and history of relatively severe hemolysis, chronic leg ulcers, and mild pulmonary hypertension presented with a new ischemic stroke. Recent research has suggested a syndrome of hemolysis-associated vasculopathy in patients with sickle cell disease, which features severe hemolytic anemia and leads to scavenging of nitric oxide and its biochemical precursor l-arginine. This diminished bioavailability of nitric oxide promotes a hemolysis-vascular dysfunction syndrome, which includes pulmonary hypertension, cutaneous leg ulceration, priapism, and ischemic stroke. Additional correlates of this vasculopathy include activation of endothelial cell adhesion molecules, platelets, and the vascular protectant hemeoxygenase-1. Some known risk factors for atherosclerosis are also associated with sickle cell vasculopathy, including low levels of apolipoprotein AI and high levels of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase. Identification of dysregulated vascular biology pathways in sickle vasculopathy has provided a focus for new clinical trials for therapeutic intervention, including inhaled nitric oxide, sodium nitrite, L-arginine, phosphodiesterase-5 inhibitors, niacin, inhaled carbon monoxide, and endothelin receptor antagonists. This article reviews the pathophysiology of sickle vasculopathy and the results of preliminary clinical trials of novel small-molecule therapeutics directed at abnormal vascular biology in patients with sickle cell disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.